ERBB2 and breast carcinoma: The VIKtorI-1 clinical trial (NCT05501886) (Study Details Gedatolisib Plus Fulvestrant With or Without Palbociclib vs. Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer VIKTORIA-1 ClinicalTrials.gov, 2023) evaluated the efficacy of gedatolisib in the treatment of advanced inoperable or metastatic HR+/HER2-patients.